ABUS

Arbutus Biopharma (ABUS)

About Arbutus Biopharma (ABUS)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Details

Daily high

$4.62

Daily low

$4.42

Price at open

$4.55

52 Week High

$5.10

52 Week Low

$2.70

Market cap

852.0M

Dividend yield

0.00%

Volume

4.2M

Avg. volume

1.3M

P/E ratio

-19.97

Arbutus Biopharma News